NI-0801 in Allergic Contact Dermatitis

NCT01244607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2010-11-19

No results posted yet for this study

Summary

The purpose of the study is to assess the effect of a single dose of NI-0801 on the severity of nickel-induced allergic contact dermatitis.

Conditions

  • Allergic Contact Dermatitis

Interventions

DRUG

Placebo

single i.v. administration

DRUG

NI-0801

single i.v. administration

Sponsors & Collaborators

  • Light Chain Bioscience - Novimmune SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01244607 on ClinicalTrials.gov